Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.56 |
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.48 |
| ▸ | KDR | P35968 | 8/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765016 | 0.93 | LCK (0.61) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL5471596 | 0.90 | LCK (0.54) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL11888972 | 0.87 | LCK (0.56) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2264429 | 0.83 | LCK (0.56) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL4772175 | 0.83 | LCK (0.60) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL4768484 | 0.82 | BRAF (0.59) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL4764961 | 0.81 | BRAF (0.56) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL4763359 | 0.81 | LCK (0.56) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL11967615 | 0.81 | LCK (0.53) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL11889147 | 0.80 | BRAF (0.52) | LCKBRAFMAPK14KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |